Les 100 médicaments essentiels. Une approche de médecine interne = 100 essential drugs. An internal medicine approach

Déclaration d'intérêts : B. Grosbois : expert pour Actélion, Celgene, Octapharma, Shire. Recherche subventionnée par LFB, Janssen, Genzyme. L. Guillevin : conseiller scientifique Actélion, expert pour (et conférences rémunérées par) GSK, CSL, Roche. L. Guillevin estime cependant n'avoir pas de conflit d'intérêt concernant le présent travail. C. Le Jeunne : expert pour Roche, Sanofi, Novartis, BSM, UCB. Essais thérapeutiques en cours pour Bayer, Pfizer, BMS. P. Morlat : expert pour Gilead, ViiV Health Care, BMS, Abbott, MSD. Ph. Morlat estime cependant n'avoir pas de conflit d'intérêt concernant le présent travail. P. Arlet, O. Aumaitre, J. Cosserat, A. Kettaneh, C. Massot et M. Thomas : aucun conflit d'intérêt.International audiencePURPOSE: Up to 4600 drugs in about 15,000 pharmaceutical forms are available in France which may be a source of misuse with increased occurrence of side effects and costs. While the World Health Organization is encouraging each developed country to work out its own list of essential drugs. The list provided in 2008 by the French Office for the safety of health products has had so far limited impact on practice, so it became obvious to a group of internists to work out a "wise list" of 100 essential medicines covering 95% of the disorders observed in France. METHODS: In June 2011, 10 internists agreed to each provide a list of 100 essential medicines, according to individual experience. In December 2011, a meeting of the participants provided a list as initial consensus and mandated five among them to make proposals for those areas neglected by too many participants or in which needless dispersion of medicines was stated. After internet-facilitated exchanges, an additional list was validated in mild-January 2012. RESULTS: Fifty-four drugs were included in the list of initial consensus (including nine selected by all 10 participants), and 46 in the additional list. So the final "wise list" included 100 drugs. In June 2012, 56 of these drugs were available as generics. This list was compared to those lists set out by five countries in the European Union. CONCLUSION: Generating such a list is feasible. Undoubtedly still non-comprehensive, this list will benefit from the expertise of 14 general practitioners who are currently working out a similar list across France. The final list will be submitted for validation by the French associations of generalist teachers and Internists

Suivi évolutif des gammapathies monoclonales de signification indéterminée (étude rétrospective de 190 patients)

RENNES1-BU Santé (352382103) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

ANALYSE EPIDEMIOLOGIQUE ET CLINIQUE DES AMYLOSES DIAGNOSTIQUEES AU CHRU DE RENNES (ETUDE PROSPECTIVE DE 1995 A 1999)

RENNES1-BU Santé (352382103) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Systemic light chain amyloidosis and Sjogren syndrome: an uncommon association.

International audienceSjogren syndrome is associated with lymphoproliferative disease in 7% of cases; however, association with AL amyloidosis is uncommon. We present a patient who presented simultaneously with Sjogren syndrome (supported by dry mouth, positive Schirmer's test, anti-Ro/SSA antibodies, and a lower lip salivary gland biopsy) and AL amyloidosis revealed by heart failure without myeloma. Although is it know that amyloidosis can masquerade as Sjogren syndrome, the occurrence of simultaneous AL amyloidosis and primary Sjogren syndrome has been reported rarely

Analytical performance of the serum free light chain assay

Peer Reviewe

Spontaneous megakaryocytic colony formation does not discriminate between essential thrombocythemia and polycythemia vera.

International audienceLaboratory detection of spontaneous growth of colony-forming unit-megacaryocytes (CFU-MK), allowing us to distinguish essential thrombocythemia (ET) from reactive thrombocytosis, is therefore useful for the diagnostic of this myeloproliferative disorder. Whether CFU-MK assays allow us to discriminate at least partly between ET and other myeloproliferative disorders such as polycythemia vera (PV) remains, however, to be established. To gain insights about this point, we have performed CFU-MK cultures from bone marrow cells of patients diagnosed with ET (n = 42) or PV (n = 50) using a standardized collagen-based serum-free method. Spontaneous growth of CFU-MK was similarly detected in both 40/42 patients with ET and 47/50 patients with PV. These data suggest clearly that the CFU-MK assay is useful to detect not only ET, but also PV, but fails to discriminate, even partly, between these two myeloproliferative disorders

Comparison of JAK2 V617F burden quantitation by two different quantitative-polymerase chain reaction methods.

International audienc